A Director at Spark Therapeutics (NASDAQ: ONCE) is Selling Shares

By George MacDonald

Yesterday, a Director at Spark Therapeutics (NASDAQ: ONCE), Anand Mehra, sold shares of ONCE for $1.38M.

Following Anand Mehra’s last ONCE Sell transaction on November 12, 2015, the stock climbed by 1.7%. In addition to Anand Mehra, one other ONCE executive reported Sell trades in the last month.

Based on Spark Therapeutics` latest earnings report from September 30, the company posted quarterly revenue of $1.3M and GAAP net loss of $16.9M. In comparison, last year the company earned revenue of $0 and had a net profit of $0. The company has a one year high of $79.50 and a one year low of $36.96. Currently, Spark Therapeutics has an average volume of 335.7k.

Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $80.67, reflecting a -28.4% downside.

Looking at blogger coverage of ONCE, there is a 100% Bullish tendency on the stock, in relation to an 80% average bullish tendency within the Healthcare sector.

Over the last 3 months, the insider sentiment on Spark Therapeutics has been negative based on 25 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

Spark Therapeutics Inc is a gene therapy company. The Company is engaged in developing one-time, life-altering gene therapy treatments to transform the lives of patients and re-imagine the treatment of debilitating diseases.